US 10166242
Optimizing mifepristone levels for Cushing's patients
granted A61KA61K31/122A61K31/135
Quick answer
US patent 10166242 (Optimizing mifepristone levels for Cushing's patients) held by Corcept Therapeutics Incorporated expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/122, A61K31/135, A61K31/136, A61K31/567